GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has announced a significant leadership change that will reshape its financial operations across the Asia Pacific region. Juby Chandy, the company's current Chief Financial Officer, is set to assume a new role as Vice President, Finance for the Asia Pacific (APAC) region, effective December 1, 2025.

New Role and Responsibilities

In his new position, Chandy will be responsible for providing strategic leadership to the finance functions across GSK's Asia Pacific markets. This move signifies GSK's commitment to strengthening its financial operations and strategy in the APAC region.

Transition Period

During the transition, Chandy will continue to serve as the Chief Financial Officer of GlaxoSmithKline Pharmaceuticals Limited until a successor is appointed. This approach aims to ensure continuity in the company's financial leadership while the search for a new CFO is underway.

Official Announcement

The company made this announcement in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The official disclosure was made to both the BSE Limited and the National Stock Exchange of India Limited on November 19, 2025.

Leadership Change Details

This strategic move by GlaxoSmithKline Pharmaceuticals underscores the company's focus on enhancing its financial leadership across the Asia Pacific region. As Juby Chandy prepares to take on this expanded role, the appointment of a successor for the Chief Financial Officer position will be a key development to watch in the coming months.

GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) reported a 2.6% year-on-year decline in revenue for the second quarter of fiscal year 2026, primarily due to supply chain disruptions and GST reform impacts. Despite these challenges, the company managed to improve its EBITDA margins and maintain market share in key segments.

Financial Performance

GSK Pharma's Q2 FY2026 financial results showcase a mixed performance:

Key Highlights

• Supply Chain Disruption: A fire incident at a key contract manufacturing organization (CMO) impacted revenue by approximately ₹40.00 crores.
• GST Reform Impact: Transitionary effects of GST reforms resulted in a ₹30.00-32.00 crores revenue impact.
• Margin Improvement: Despite revenue challenges, EBITDA margins improved by 250 basis points to 34.4%, driven by cost savings and better product mix.
• Market Share: The company maintained its market share at 27.6%.
• Oncology Launch: GSK Pharma launched its oncology business on August 15, 2025, introducing Jemperli for endometrial cancer and Zejula for ovarian cancer.

Segment Performance

• General Medicines: Faced headwinds due to supply issues and softer market growth in acute segments.
• Vaccines: Demonstrated strong double-digit growth in both pediatric and adult segments.
• Specialty Products: Nucala and Trelegy grew over 20%.

Management Commentary

Bhushan Akshikar, Managing Director of GSK Pharma, stated, "Moving forward from Q3 onwards, we definitely expect to not only stabilize but start building the inventories. We have very robust business continuity plans in place."

Juby Chandy, Chief Financial Officer, added, "We will be able to sustain the margins. We are seeing stable prices on raw materials and hence we will be able to sustain the gross margins."

Future Outlook

• The company remains committed to its double-digit growth ambition for the coming quarters.
• Supply constraints are expected to be resolved from Q3 onwards.
• GSK Pharma continues to focus on expanding its presence in specialty areas, including oncology.
• The company is participating in 16 global trials of its assets in India, aiming to accelerate the launch of innovative medicines and vaccines.

As GSK Pharma approaches its 102nd year of operations in India, it continues to navigate challenges while maintaining its focus on growth and innovation in the pharmaceutical sector.